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ABSTRACT 
Despite major efforts devoted to understanding the phenomenon of prion transmissibility, it is 
still poorly understood how this property is encoded in the amino acid sequence. In recent years, 
experimental data on yeast prion domains allows to start at least partially decrypting the 
sequence requirements of prion formation. These experiments illustrate the need for intrinsically 
disordered sequence regions enriched with a particularly high proportion of glutamine and 
asparagine. Bioinformatic analysis suggests that these regions strike a balance between 
sufficient amyloid nucleation propensity on the one hand and disorder on the other, which 
ensures availability of the amyloid prone regions but entropically prevents unwanted nucleation 
and facilitates brittleness required for propagation. 
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In the cell, proteins attain the native structure through a delicate and balanced network of 
interactions, where protein folding and aggregation exert as competing pathways1, 2. In a protein 
energy landscape, amyloid-like aggregates represent an energy minimum, being usually 
thermodynamically more stable than the native conformation. This has lead to the hypothesis 
that the amyloid conformation reflects a universal mode of assembly of polypeptide chains and 
that native protein conformations are evolutionary selected metastable states2. Amyloids are 
aggregates displaying fibrillar structure, which is constituted by repetitions of a specific protein 
in a regular β-sheet conformation that runs perpendicular to the fibril axis3. In humans, amyloids 
are linked to diseases ranging from neurodegenerative conditions such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD) and Creutzfeldt-Jakob disease (CJD), to non-neuronal systemic 
and localized disorders3. On the other hand functional amyloids, i.e. proteins that exploit the 
amyloid fold for evolutionary selected biological functions, have been discovered in diverse 
species, including human4. The roles fulfilled by these functional amyloids range from obligate 
amyloid structures required for scaffolding and/or movement to conditional amyloids such as the 
yeast prions that can be triggered by environmental factors5. Whether obligate or conditional, 
the natural selection of amyloid structure as a functional motif indicates that these properties are 
likely sequence specific. Whereas the attainment and sustainment of the native structure relies 
on cooperative interactions involving most, if not all, of the sequence of a protein domain6, 7, the 
now widely accepted ‘short stretch hypothesis’ states that amyloid formation in contrast is 
nucleated by short regions of the amino acid sequence named aggregation hot-spots (HS), 
Aggregation Prone Regions (APR) or Aggregation Prone Sequences (APS)8, 9. The short stretch 
model led to the development of over twenty algorithms that more or less successfully predict 
protein aggregation and amyloid formation based on the identification of specific b-aggregation 
and amyloid-prone regions in the polypeptide sequences 10-12. In disease-associated amyloids 
these regions are generally between 5 and 10 residues in length 13 . 
Prions are considered a subclass of amyloids in which protein aggregation becomes self-
perpetuating and infectious. The phenomenon is known mostly as a neuronal pathology in 
mammals but in fungi prions play a crucial role in epigenetic inheritance 14-16. Importantly, 
despite the overlapping conformational properties of amyloids and prions, only a handful of 
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amyloids are currently considered to display at least partial prion capacity under natural 
conditions 16. As a result, b-aggregation and amyloid predictors are still a long way from 
correctly detecting prion sequences in proteomes 17. In fact, the sequence characteristics that 
make a protein sequence a prion have been elusive for years. Moreover, at first glance, the 
sequence features conferring prion capacity to prion protein in mammals (PrP) appear to differ 
remarkably from those determining prion behaviour in fungi. 
Yeast prions are the best characterized transmissible amyloids, thus being excellent model 
systems to address the determinants of concomitant amyloid formation and propagation 18. In 
these proteins, prion formation from an initially soluble state involves a structural amyloid 
conversion driven by specific, relatively large, unstructured domains enriched in 
glutamine/asparagine (Q/N) residues 18. Interestingly, protein domains displaying this sequence 
signature are over-represented in eukaryotic proteomes relative to prokaryotes, suggesting that 
prion-like conformational transition might have evolved as a mechanism for regulating gene 
function at the protein level in eukaryotes19. It should be mentioned, however, that PrP, the 
archetypical mammalian prion, lacks these sequential features. 
In order to explore the repertoire of prion proteins in Saccharomyces cerevisiae the Lindquist 
group conducted a genome-wide bioinformatics survey using a hidden Markov sequence model 
to identify putative candidates on the basis of their compositional similarity to known prion 
forming domains (PFDs) 20 and used experimental validation to identify the bone-fide PFDs in 
their predictions. These results are at the core of several algorithms for prion domain prediction, 
all relying on the analysis of amino acid sequences 17, 21-24. These programs are constructed on 
two alternative models for amyloid formation by prion-like domains (Figure 1): (1) The 
compositional model relying on the establishment of a large number of weak interactions 17 and 
(2) our model, which proposes ‘classical’ nucleation by short amyloidogenic stretches, whose 
amyloid propensity is modulated by the structural context 24. Despite the mechanistic difference 
between algorithms, the advent of accurate computational tools to detect yeast prion domains 
opens new and exciting possibilities, allowing the exploration of proteomes for the discovery of 
novel and hitherto unexpected Q/N-enriched domains that may drive conformational conversion 
in novel prion proteins. Indeed, recent studies have revealed that over 250 human proteins 
display prion-like stretches in regions with high presence of uncharged polar residues and 
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glycine, including several heterogeneous nuclear ribonucleoproteins (hnRNPs) related to 
neurodegenerative diseases such as familial amyotrophic lateral sclerosis (fALS) 25. 
In the light of these advances, the requirements for a polypeptide sequence to act as a prion 
begin to be defined. In our view, for a protein sequence to become a Q/N enriched prion, three 
essential conditions appear to be required: 
 
Requirement 1: A short amyloid-prone region able to trigger amyloid formation in a sequence 
specific manner. These amyloid cores should, however, possess distinctive features, since both 
a high aggregation rate and an elevated fragmentation capacity are necessary in prions in order 
to attain the number of propagons or seeds required for spreading and propagation 26, 27. Thus, 
while a certain amyloid nucleation capacity favouring a sufficiently high aggregation rate is 
absolutely necessary, the final amyloid aggregate should at the same time display brittleness, a 
property that facilitates an increase in the number of nucleation events per cell. Accordingly, in 
contrast to most amyloids, the aggregation reaction should not be nucleated in PFDs by an 
extremely strong and highly hydrophobic amyloid core. 
Requirement 2: The amyloid-prone region has to be located in a structurally disordered region, 
that permits its self-assembly without the necessity of conformational unfolding. The PFDs of all 
known Q/N enriched yeast prions display this property 18, 20. The location of the amyloid core in 
large unstructured regions favours the acquisition of the b-cross motif without large 
conformational rearrangements and may at the same time promote the brittleness mentioned in 
requirement 1. Moreover, the disordered region may act as a so-called ‘entropic bristle’ 27, 28, 
which would reduce the overall aggregation propensity and could allow for a better biological 
control of the nucleation event, which is discussed more in detail in requirement 3. 
Requirement 3: PFDs have to posses an amino acid composition allowing the protein to remain 
in a soluble state under physiological conditions while keeping intact a cryptic amyloid capacity. 
Stress situations promoting increased local protein concentration, as well as the presence of 
preformed amyloid seeds, might alter the delicate equilibrium between native/soluble and 
amyloid/insoluble states, providing means to control the nucleation of amyloid aggregation and 
hence the onset of the prion phenotype. If we recapitulate requirements (1) and (2), clustering in 
the same sequence region amino acid residues with a significant amyloid propensity together 
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with residues promoting structural disorder would favour prion capacity. Only five amino acid 
residues seem to unite these two essential properties, i.e. amyloid propensity and structural 
disorder, according to FoldIndex29 and Waltz30 algorithms: N, Q, Y, S and W. (Figure 2). 
Interestingly enough N, Q, Y, S are, in this order, the most over-represented residues in bona-
fide prion domains, relative to their frequency in the protein universe22, with odds ratios of 5.70, 
4.13, 1.72 and 1.66, respectively. In this context, N and Q residues show medium amyloid 
propensity, allowing the formation of amyloids with moderate strength, while at the same time 
are the amyloidogenic residues that more benefice disorder. This provides a rational basis for 
the strong over-representation of these particular residues in the PFDs of yeast. In good 
agreement with its higher frequency, N is the residue that best balances amyloid and disorder 
propensity and thus the preferred residue to support prion behaviour. It is important to point out, 
however, that poly-N or poly-Q, these later being involved in a number of ataxias31, are not 
expected to display a prion-like behaviour since they lack requirement 1, that is, a specific 
region able to selectively nucleate ordered amyloid formation. 
 
Hydrophobic amino acids are under-represented in Q/N-rich yeast PFDs, likely because a high 
proportion of these residues would render the protein excessively aggregation-prone and/or 
result in too strong amyloid assemblies. Despite the presence of a reduced number of 
hydrophobic residues in PFDs has been shown to bust prion formation and amyloid formation 
32, Y is the only hydrophobic residue over-represented in these domains. It has been proposed 
that this might respond to the fact that aromatic residues might facilitate both prion formation 
and chaperone dependent prion propagation33. However, F is indeed under-represented in 
PFDs with an odds ratio of 0.72 and the Y/F relationship between odds ratios in PFDs is 2.4, 
suggesting that the additional hydroxyl group in Y should provide and additional advantage, 
which in our opinion is allowing a better balance of amyloid propensity and intrinsic disorder. 
Despite its aromatic character, W is one of the most under-represented residues in prion 
domains with and odd ratio of 0.091, only C, which is able to crosslink covalently polypeptide 
chains, being less frequent22. The absence of W in PFDs is best explained by its particular 
structure, wherein the indole group may not be easily placed in b-cross structures due to of 
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steric impediments, being indeed depleted relative to F and Y in functional and pathogenic 
amyloids34. 
The two alternative models used to identify prion domains (Figure 1) coincide in the 
requirement of a relatively large disordered region in yeast PFDs. However, one prion model 
support the view of amyloid formation in PFDs resulting from a bias in sequence composition 
favouring a large number of weak interactions over a wide sequence stretch 17 whereas the 
alternative model supports prion behaviour to emerge from the preferential nucleation by 
specific and localized short amyloid-prone stretches embedded in the wider disordered region 
24. Despite the apparent contradiction between these two views, indeed the second model just 
pursues to delimitate the aggregation driving force of the amyloid-cores embedded in the prions 
domains defined by the compositional model. In this way, the first composition based methods 
to predict potential yeast prions proposed a minimal core of 60 residues20. This further evolved 
into a method employing a 41 amino acid sliding window for compositional analysis, denoting 
that the initial 60 residues window was larger than actually required 17. We proposed to reduce 
this size even further to account for a 21 amino acid core, based on the length of the core of 
HET-s PFD, the unique protein for which an atomic-resolution structure of the infectious fibrillar 
state available to date 24, 35, which displays a b-arcade conformation36. The excellent 
performance of our method, based on a preferential nucleation by a short amyloid-prone 
stretches, lead us to believe not only that a 21 residues core is indeed sufficient for prediction, 
but also that the ‘classical’ short stretch nucleation model applies to prions in a similar manner 
as it does for ‘classic’ amyloids, the main differences being that in prions amyloid nucleating 
stretches might fold into b-strand-turn-b-strand elements and that they are strongly modulated 
by the entropy of the sequence context in which they are embedded, i.e. the degree of structural 
disorder will determine both the sensitivity for amyloid nucleation as well as the ability of formed 
fibrils to break up and provide additional propagons. 
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Figure 1. Two models for amyloid structure formation in Q/N-rich prion-like domains. The 
compositional model relies on the establishment a large number of weak interactions whereas 
the amyloid-stretch model proposes the existence of a preferential short nucleating sequence 
whose amyloid propensity is modulated by its structural context. 
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Figure 2. Balance between amyloid and structural propensities in natural amino acids. 
Residues rendering ordered and disordered 21-residues long homo-polymers according to 
FoldIndex14 are shown in green and yellow circles, respectively. The amyloid propensity of 
these stretches was calculated with Waltz30. The four more over-represented residues in yeast 
PFDs are circled by discontinuous lines, red indicates odd ratios > 4.0 and blue odd ratios > 1.5, 
relative to the composition of the protein universe22. 
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